Acute Myeloid Leukemia: Current Therapy, Challenges, and Future Therapeutic Candidates


Author(s)
Hamid Ali Nagi Al-Jamal
School of Biomedicine, Faculty of Health Sciences, Universiti Sultan Zainal Abidin, Kuala Terengganu, Terengganu 21300, Malaysia.

Belal Almajali
Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman, Jordan.

Maysa Alhawamdeh
Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Mutah University, Al-Karak, Jordan.

Hanan Kamel M. Saad
School of Biomedicine, Faculty of Health Sciences, Universiti Sultan Zainal Abidin, Kuala Terengganu, Terengganu 21300, Malaysia.

ISBN 978-81-966449-7-0 (Print)
ISBN 978-81-966449-5-6 (eBook)
DOI: 10.9734/bpi/mono/978-81-966449-7-0

This book focuses on the past, current treatment and future therapeutic candidates of acute myeloid leukemia (AML) as well as the challenges facing clinicians and researchers. Therefore, this book is a comprehensive exploration of the treatment for one of the most common hematological malignancies in adults.

In the following pages, we described the landscape of AML, delving deep into its molecular aspects such as, diagnostical and therapeutical targets, current treatment modalities, and the challenges in treatment particularly the resistant. AML has been intensively studied. However, the suitable treatment of AML stills unmet, pushing the boundaries of our molecular understanding vitally needed.

This book specifically aimed to capture the critical advancements for emerging future therapeutic candidates that could lead to potential management of AML. We began with an exploration of the common genetic abnormalities and mutations and epigenetic modifier in this leukemia, providing a solid foundation for understanding the molecular aspects of AML. From which, we clearified the clinical landscape, discussing the developments in diagnosis, risk stratification, and treatment options. We also explored the treatment challenges faced ranging from bone marrow transplantation to the management of therapy-related complications and bioactive compounds against AML which could be a future candidate for such cancer.

So, we hope this book will be a valuable resource for medical, biomedical students, and cancer researchers to navigate the complexities of AML and pave the way for a brighter future.

Thank you for embarking on fighting leukemia and other cancers.

 

Media Promotion

Content

Acute Myeloid Leukemia: Current Therapy, Challenges, and Future Therapeutic Candidates

Hamid Ali Nagi Al-Jamal , Belal Almajali , Maysa Alhawamdeh , Hanan Kamel M. Saad

Acute Myeloid Leukemia: Current Therapy, Challenges, and Future Therapeutic Candidates, 20 October 2023, Page 1-52
https://doi.org/10.9734/bpi/mono/978-81-966449-7-0

Acute myelogenous leukemia (AML) is the most common leukemia among adults. It is characterized by somatic mutations or genetic alterations that lead to neoplastic changes and clonal proliferation. Historical treatment paradigms remained largely unchanged throughout the 20th and early 21st centuries, the current treatment of AML stills chemotherapy and stem cell transplantation. Even though advancements in understanding the genetic variances associated with AML have introduced promising new therapeutic options that could potentially improve the outcomes. Tyrosine kinase inhibitors (TKI) such as PKC-412 are one of the recent treatment options that showed successful results. However, in addition to the cost, evidence of resistance to these TKI has been reported. Therefore, searching for alternative, cheaper, available, and effective treatments for AML is vitally needed. This book aimed to be suitable for medical and biomedical students to understand the pathogenesis of AML in molecular aspects and the possible treatment of such malignancies. Therefore, the pathogenesis, therapeutic targets, challenges, and possible therapeutic candidates have been discussed in detail in this book.